ARCHIMED Acquires ZimVie

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED (MED Platform II) Acquires Jeisys Medical

September 11, 2024

Medical Devices

ARCHIMED, via its MED Platform II fund, has agreed a ₩990 billion take-private acquisition of Jeisys Medical, a Seoul-based developer of energy-based aesthetic medicine devices. The transaction will delist Jeisys from the Korea Exchange and support the company’s international expansion, with founder Dong Hwan Kang reinvesting a material portion of his proceeds into the privatized business.

ARCHIMED Acquires Majority Stake in Cardioline

November 17, 2021

Medical Devices

Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Groupe Laboratoire Rivadis

September 8, 2025

Consumer Products

ARCHIMED, a healthcare-focused private equity firm, has acquired Groupe Laboratoire Rivadis, a French developer and manufacturer of dermo-cosmetics and hygiene products (brands include Rivadouce, Milton and Auriège). The seller, majority shareholder Christian Lainé, is reinvesting a meaningful portion of proceeds; ARCHIMED plans to support Rivadis' growth and strengthen its position in the consumer health / dermo-cosmetics market.